医渡科技(02158.HK)授出合共357万股奖励股份
格隆汇6月30日丨医渡科技(02158.HK)发布公告,于2025年6月30日,公司根据首次公开发售后股份奖励计划,通过发行新股份向115名奖励承授人(包括114名雇员参与者及1名服务提供商)授出合共357万股奖励股份,占于本公告日期全部已发行股份(不包括库存股)约0.34%。
首次公开发售后股份奖励计划旨在为获选定参与者(包括雇员参与者及服务提供商)提供获取公司所有权权益的机会,藉以鼓励获选定参与者为公司及股东整体利益积极工作,提高公司及其股份的价值。透过首次公开发售后股份奖励计划,公司可以灵活方式留任、激励、奖励、酬谢、补偿合资格人士及╱或向彼等提供福利。董事会认为,该等奖励将确保公司的长期利益,并激励奖励承授人为公司的发展作出贡献。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.